WHO ICTRP trial
Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III…
JPRN-UMIN000003272 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000003272 |
|---|---|
| Public title | Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS) |
| Scientific title | Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS) - Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS) |
| Primary sponsor | Japan Clinical Oncology Group(JCOG) |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase III |
| Countries | Japan |
| Conditions | Stage III colorectal cancer |
| Interventions | A: capecitabine. Patients in this group receive 8 courses of oral capecitabine, at a dose of 1,250 mg/m2 twice daily for 14 days every 21 days. B: S-1. Patients in this group receive 4 courses of oral S-1, at a dose of 40 mg/m2 twice daily… |
| Registration date | Jan 3, 2010 |
| Target size | 1550 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: